Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.64 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.61 |
| ▸ | APLNR | P35414 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 4/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.58 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.58 |
| ▸ | GLP1R | P43220 | 2/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.58 |
| ▸ | NPY1R | P25929 | 2/20 | 0.57 |
| ▸ | NPY2R | P49146 | 2/20 | 0.57 |
| ▸ | CCKBR | P32239 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30008485 | 0.98 | CALCR (0.62) | CALCRC5AR1APLNRF2CXCR4 | |
| SCHEMBL29767745 | 0.98 | CALCR (0.63) | CALCRC5AR1APLNRF2CXCR4 | |
| SCHEMBL31691514 | 0.97 | APLNR (0.62) | CALCRC5AR1APLNRF2CXCR4 | |
| SCHEMBL30444134 | 0.95 | APLNR (0.63) | CALCRC5AR1APLNRF2CXCR4 | |
| SCHEMBL31691539 | 0.95 | APLNR (0.61) | CALCRC5AR1APLNRF2CXCR4 | |
| SCHEMBL30432875 | 0.93 | CALCR (0.65) | CALCRC5AR1APLNRF2GLP1R | |
| SCHEMBL30444321 | 0.93 | APLNR (0.63) | CALCRC5AR1APLNRF2CXCR4 | |
| SCHEMBL31182976 | 0.91 | CALCR (0.70) | CALCRAPLNRF2CXCR4GLP1R | |
| SCHEMBL30495635 | 0.91 | NPY2R (0.66) | CALCRF2HCRTR1HCRTR2GLP1R | |
| SCHEMBL31182622 | 0.90 | CALCR (0.72) | CALCRF2GLP1RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4706671-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4025592-B1 | CONJUGATED HEPCIDIN MIMETICS FOR USE IN TREATING OF POLYCYTHEMIA VERA | PROTAGONIST THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12234300-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4501952-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240209024-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | PROTAGONIST THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11753443-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220372099-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| US-11472842-B2 | Analogues of hepcidin mimetics with improved in vivo half lives | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| CN-114729022-A | Conjugated hepcidin mimetics | 领导医疗有限公司 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472842-B2 | Analogues of hepcidin mimetics with improved in vivo half lives | HAMP, VIP, HDGF | CALCR 141/4885C5AR1 317/4885APLNR 20/4885 |
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | CALCR 148/4885C5AR1 122/4885APLNR 13/4885 |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | HAMP, VIP, HDGF | CALCR 148/4885C5AR1 122/4885APLNR 13/4885 |
| US-20240209024-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | CALCR 148/4885C5AR1 122/4885APLNR 13/4885 |
| US-12234300-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | CALCR 148/4885C5AR1 122/4885APLNR 13/4885 |
| US-11753443-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | CALCR 148/4885C5AR1 122/4885APLNR 13/4885 |
| US-20220372099-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, HDGF, FTH1 | CALCR 199/4885C5AR1 282/4885APLNR 30/4885 |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | CALCR 966/4885C5AR1 1005/4885APLNR 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.